[{"id":"39c3282f-51bb-4fb8-ab95-8b0dcb862709","acronym":"","url":"https://clinicaltrials.gov/study/NCT05506956","created_at":"2023-08-14T10:11:09.789Z","updated_at":"2024-07-02T16:35:00.814Z","phase":"Phase 1","brief_title":"Post-transplant Flotetuzumab for AML","source_id_and_acronym":"NCT05506956","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/20/2022","start_date":" 10/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-27"},{"id":"2e1f45d7-114f-4454-9867-53cc8e8641d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681105","created_at":"2021-01-19T20:46:40.489Z","updated_at":"2024-07-02T16:35:25.698Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","source_id_and_acronym":"NCT04681105","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 05/05/2026","primary_completion_date":" 05/05/2026","study_txt":" Completion: 05/05/2026","study_completion_date":" 05/05/2026","last_update_posted":"2023-12-20"},{"id":"50591c7e-2bb2-4a10-8880-29d3224dc148","acronym":"PEPN1812","url":"https://clinicaltrials.gov/study/NCT04158739","created_at":"2023-12-11T17:16:23.292Z","updated_at":"2024-07-02T16:35:26.619Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04158739 - PEPN1812","lead_sponsor":"Children's Oncology Group","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-12-11"},{"id":"b7c01580-5ee3-4f13-b16b-b440889f56d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04678466","created_at":"2023-08-14T10:11:05.005Z","updated_at":"2024-07-02T16:36:09.693Z","phase":"","brief_title":"Flotetuzumab Expanded Access Program","source_id_and_acronym":"NCT04678466","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-05-30"},{"id":"f26ff57b-a92c-4ad3-b4f7-844a5f91cc83","acronym":"HOVON162AML","url":"https://clinicaltrials.gov/study/NCT05063123","created_at":"2021-09-30T22:53:06.373Z","updated_at":"2024-07-02T16:36:19.229Z","phase":"Phase 2","brief_title":"Study to Assess an Interphase Cycle With Flotetuzumab.","source_id_and_acronym":"NCT05063123 - HOVON162AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2021-12-22"},{"id":"e4d83257-c80b-4e1e-8b12-fb24718335d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03739606","created_at":"2021-01-18T18:18:56.025Z","updated_at":"2024-07-02T16:36:37.235Z","phase":"Phase 2","brief_title":"Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer","source_id_and_acronym":"NCT03739606","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 10/20/2020","primary_completion_date":" 10/20/2020","study_txt":" Completion: 10/20/2020","study_completion_date":" 10/20/2020","last_update_posted":"2020-12-17"}]